Lexicon Pharmaceuticals Crescita futura
Criteri Future verificati 1/6
Lexicon Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 4.7% e 18% all'anno. Si prevede che l'EPS crescerà di 21.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -52.6% in 3 anni.
Informazioni chiave
4.7%
Tasso di crescita degli utili
21.75%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 14.4% |
| Tasso di crescita dei ricavi | 18.0% |
| Rendimento futuro del capitale proprio | -52.64% |
| Copertura analitica | Low |
| Ultimo aggiornamento | 09 May 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • May 11
LXRX: Phase 3 Pain Readiness And Partnership Prospects Will Drive Repricing
Analysts have lifted their fair value estimate for Lexicon Pharmaceuticals from $3.36 to $3.72, pointing to higher price targets from multiple firms and increased confidence in the pilavapadin program following recent clinical and regulatory progress. Analyst Commentary Recent Street research on Lexicon Pharmaceuticals highlights a mix of optimism around pilavapadin and caution around execution and deal timing, which feeds directly into fair value assumptions and risk assessments.Aggiornamento della narrazione • Apr 25
LXRX: Phase 3 Pain Program And Partnership Expectations Will Drive Repricing
Narrative Update Analysts have raised their price targets on Lexicon Pharmaceuticals to a range of about $2.30 to $6.00. They cite increased confidence in the pilavapadin program, particularly a higher assessed probability of success and expectations for a potential partnership on the Phase 3 ready asset.Aggiornamento della narrazione • Apr 06
LXRX: Phase 3 Pain Program Progress And Partnership Expectations May Support Upside
Analysts have raised their average price targets for Lexicon Pharmaceuticals, with moves such as Citi's shift from $2.10 to $2.30 and H.C. Wainwright's adjustment from $4 to $6, citing a higher assumed probability of success for pilavapadin and progress on clinical and regulatory work that they see as reducing program risk. Analyst Commentary Recent Street research on Lexicon Pharmaceuticals points to a generally constructive tone, with higher price targets linked to views on pilavapadin and the perceived risk profile of the pipeline.Aggiornamento della narrazione • Mar 21
LXRX: Phase 3 Pain Program And Key Partnership Potential May Drive Upside
Analysts have nudged the fair value estimate for Lexicon Pharmaceuticals higher to $3.36 from $3.32, reflecting updated assumptions around revenue growth, profit margins and future P/E multiples following recent price target increases to $2.30 at one firm and $6 at another. Analyst Commentary Recent research updates offer a mixed picture on Lexicon Pharmaceuticals, with higher price targets tied closely to progress on its pipeline, particularly pilavapadin, and expectations around future execution.Aggiornamento della narrazione • Mar 07
LXRX: Phase 3 Pain Program And Partnership Prospects Will Support Future Upside
Analysts have raised their price targets on Lexicon Pharmaceuticals, with one moving from $4 to $6, citing a higher assumed probability of success for pilavapadin and the potential for an important partnership on this Phase 3 ready program. Analyst Commentary Bullish Takeaways Bullish analysts see the higher assumed probability of success for pilavapadin, at 30% versus the prior 15%, as a key input to higher valuation for Lexicon, particularly as the program is described as Phase 3 ready.Aggiornamento della narrazione • Feb 21
LXRX: Phase 3 Pain Program Progress Will Support Stronger Future Earnings Power
Analysts have raised their price target on Lexicon Pharmaceuticals by $0.20, citing updated assumptions around discount rates, profit margin expectations, and future P/E levels that refine their view of the stock's risk and earnings power. Analyst Commentary Analysts raising the price target by $0.20 are fine tuning their models rather than making a sweeping call, and their commentary gives you a sense of what they think could go right or wrong from here.Aggiornamento della narrazione • Jan 27
LXRX: Phase 3 Pain Program Progress Will Support Higher Future Earnings Power
Analysts have nudged their price target for Lexicon Pharmaceuticals higher, with fair value moving from US$2.75 to US$2.92 as they factor in updated views on discount rates, revenue growth, profit margins and future P/E multiples. Analyst Commentary Analysts updating their models around Lexicon Pharmaceuticals are using the new fair value estimate of US$2.92 as a reference point, linking it to assumptions on discount rates, revenue trajectories, margins and future P/E levels.Seeking Alpha • Jan 22
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward
Summary Lexicon Pharmaceuticals is downgraded to a 'Hold' rating due to repeated FDA rejections of ZYNQUISTA for T1D and uncertain near-term catalysts. LXRX plans to resubmit ZYNQUISTA’s NDA in 2026, contingent on positive safety data from the ongoing STENO1 study. Positive FDA feedback enables pilavapadin to advance into two short, registrational Phase 3 studies for diabetic peripheral neuropathic pain (DPNP). Strong cash position ($125.2M) and potential milestone payments provide runway into 2027, but execution and regulatory risks remain material. Read the full article on Seeking AlphaArticolo di analisi • Jan 22
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have had a really impressive month, gaining 28% after a shaky...Articolo di analisi • Dec 18
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Oct 02
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%
Despite an already strong run, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have been powering on, with a gain...Aggiornamento della narrazione • Aug 22
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Lexicon Pharmaceuticals' price target was revised down to $2.75 as analysts weigh mixed signals: strong Q2 results and management confidence against heightened reliance on positive upcoming PROGRESS trial data as a near-term share catalyst. Analyst Commentary Upward price target revision follows recent Q2 results exceeding expectations.Aggiornamento della narrazione • Aug 07
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Despite a sharp downgrade in revenue growth forecasts, Lexicon Pharmaceuticals’ consensus analyst price target has increased notably, supported by a lower future P/E ratio and now stands at $3.05. What's in the News Post-hoc analysis of clinical data showed sotagliflozin reduced hypoglycemia events without increased risk across kidney function subgroups in type 1 diabetes patients using optimized insulin therapy.Articolo di analisi • Jul 28
There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump
Despite an already strong run, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have been powering on, with a gain...Articolo di analisi • Jun 13
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have continued their recent momentum with a 31% gain in the last...Articolo di analisi • May 19
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts
Shareholders in Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) may be thrilled to learn that the analysts have just...Articolo di analisi • May 17
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) investors will be delighted, with the company turning in some strong...
Nuova narrazione • Apr 01
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.Seeking Alpha • Mar 28
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Summary Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted focus to becoming a clinical development-focused company. Lexicon's Phase 2b neuropathy trial technically failed but the company plans to advance to Phase 3 trials. With $238 million in cash, Lexicon has financial runway into early 2027 despite monthly burn of $7 million. I upgraded my rating from "Sell" to "Hold" but remain cautious until Lexicon establishes signs of sustainable revenue generation in the future. Read the full article on Seeking AlphaArticolo di analisi • Mar 26
Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%
The Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Oct 16
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Summary Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance, making market penetration difficult. Inpefa’s early commercial results are underwhelming, with Q2 revenue of only $1.6 million and rising SG&A costs. Lexicon has pivoted from heart failure to type 1 diabetes, where sotagliflozin could be the first SGLT2 approved for T1D in the U.S. The company’s pipeline includes LX9211 for diabetic peripheral neuropathic pain, though Phase 2 results indicate mixed efficacy and safety concerns. Given strong competition, limited market penetration, and pipeline risks, Lexicon presents a high-risk, low-reward investment opportunity. Read the full article on Seeking AlphaArticolo di analisi • Aug 08
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Aug 03
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Summary Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present. Lexicon's pipeline is getting more interesting, with LX9211 in diabetic neuropathy and a new candidate for obesity and/or metabolic disease in preclinical testing, but effectively commercializing Inpefa remains critical. Lexicon shares appear undervalued on the basis of Inpefa's commercial opportunity and the risk-adjusted opportunities in Type 1 diabetes, diabetic neuropathy, and hypertrophic cardiomyopathy, but execution risk is very high. Read the full article on Seeking AlphaSeeking Alpha • May 28
Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
Summary Lexicon Pharmaceuticals has a strong cash position and multiple late-stage assets. However, the company is facing low revenues and high expenses. Overall, Lexicon Pharmaceuticals' financial situation presents a mixed outlook for the company. Read the full article on Seeking AlphaPrevisioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 76 | -58 | N/A | N/A | 5 |
| 12/31/2027 | 20 | -88 | N/A | N/A | 5 |
| 12/31/2026 | 38 | -67 | N/A | N/A | 5 |
| 3/31/2026 | 70 | -26 | N/A | N/A | N/A |
| 12/31/2025 | 50 | -50 | -68 | -68 | N/A |
| 9/30/2025 | 71 | -69 | -73 | -72 | N/A |
| 6/30/2025 | 58 | -121 | -103 | -102 | N/A |
| 3/31/2025 | 31 | -177 | -168 | -167 | N/A |
| 12/31/2024 | 31 | -200 | -180 | -179 | N/A |
| 9/30/2024 | 5 | -216 | -208 | -208 | N/A |
| 6/30/2024 | 4 | -202 | -196 | -196 | N/A |
| 3/31/2024 | 2 | -194 | -186 | -185 | N/A |
| 12/31/2023 | 1 | -177 | -162 | -162 | N/A |
| 9/30/2023 | 1 | -158 | -135 | -133 | N/A |
| 6/30/2023 | 0 | -131 | -112 | -111 | N/A |
| 3/31/2023 | 0 | -110 | -99 | -97 | N/A |
| 12/31/2022 | 0 | -102 | -90 | -89 | N/A |
| 9/30/2022 | 0 | -97 | -90 | -90 | N/A |
| 6/30/2022 | 0 | -97 | -88 | -88 | N/A |
| 3/31/2022 | 0 | -90 | -87 | -85 | N/A |
| 12/31/2021 | 0 | -88 | -88 | -87 | N/A |
| 9/30/2021 | 0 | -68 | -100 | -98 | N/A |
| 6/30/2021 | 7 | 38 | 38 | -122 | N/A |
| 3/31/2021 | 16 | -13 | 14 | -146 | N/A |
| 12/31/2020 | 24 | -59 | 17 | -143 | N/A |
| 9/30/2020 | 33 | -104 | 27 | -133 | N/A |
| 6/30/2020 | 320 | 39 | 98 | 98 | N/A |
| 3/31/2020 | 321 | 85 | 117 | 117 | N/A |
| 12/31/2019 | 322 | 130 | N/A | 114 | N/A |
| 9/30/2019 | 330 | 164 | N/A | 111 | N/A |
| 6/30/2019 | 43 | -89 | N/A | -102 | N/A |
| 3/31/2019 | 47 | -101 | N/A | -127 | N/A |
| 12/31/2018 | 63 | -121 | N/A | -149 | N/A |
| 9/30/2018 | 81 | -126 | N/A | -155 | N/A |
| 6/30/2018 | 101 | -129 | N/A | -167 | N/A |
| 3/31/2018 | 99 | -130 | N/A | -147 | N/A |
| 12/31/2017 | 92 | -123 | N/A | -185 | N/A |
| 9/30/2017 | 80 | -133 | N/A | -200 | N/A |
| 6/30/2017 | 81 | -138 | N/A | -202 | N/A |
| 3/31/2017 | 89 | -141 | N/A | -217 | N/A |
| 12/31/2016 | 79 | -131 | N/A | -176 | N/A |
| 9/30/2016 | 188 | -22 | N/A | 139 | N/A |
| 6/30/2016 | 160 | -22 | N/A | 149 | N/A |
| 3/31/2016 | 141 | -11 | N/A | 165 | N/A |
| 12/31/2015 | 130 | -5 | N/A | 185 | N/A |
| 9/30/2015 | 24 | -94 | N/A | -86 | N/A |
| 6/30/2015 | 24 | -100 | N/A | -81 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che LXRX rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che LXRX rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che LXRX rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di LXRX ( 18% all'anno) crescerà più rapidamente del mercato US ( 11.6% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di LXRX ( 18% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che LXRX non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/20 11:10 |
| Prezzo dell'azione a fine giornata | 2026/05/20 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Lexicon Pharmaceuticals, Inc. è coperta da 12 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Andrew Tsai | Jefferies LLC |